CRISPR-Cas systems have revolutionized genetic engineering, offering a precise and efficient platform for genome editing.  This technology leverages naturally occurring bacterial defense mechanisms, utilizing guide RNA (gRNA) molecules to direct the Cas nuclease to specific DNA sequences.  Cas9, the most widely used nuclease, induces double-strand breaks, stimulating cellular repair pathways â€“ non-homologous end joining (NHEJ), often resulting in insertions or deletions, or homology-directed repair (HDR), enabling precise gene replacement or modification.  Beyond gene disruption, CRISPR has expanded to encompass base editing, employing modified Cas enzymes to achieve single-base changes without double-strand breaks, thereby minimizing off-target effects.  Furthermore, prime editing offers a more versatile approach, enabling all 12 possible base-to-base conversions and small insertions or deletions.  Despite its transformative potential, challenges remain, including off-target cleavage, delivery limitations, and ethical considerations regarding germline editing.  Ongoing research focuses on enhancing specificity, expanding targeting capabilities, and developing novel CRISPR-associated enzymes for broader applications in gene therapy, agriculture, and fundamental biological research.